Belatacept (Nulojix®)

Assessment Status Rapid Review complete
HTA ID -
Drug Belatacept
Brand Nulojix®
Indication In combination with corticosteroids and a mycophenolic acid (MPA), for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen.
Assessment Process
Rapid review commissioned 15/11/2011
Rapid review completed 23/01/2012
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended